Hermione Allen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hermione Allen has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Karla J. Cowley
Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Australia
2 shared publications - Kaylene J. Simpson
Peter MacCallum Cancer Centre
2 shared publications - Ada Koo
Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
1 shared publication - Adele K. Fielding
Centre for Blood Research, Hull York Medical School, University of York, York, United Kingdom
1 shared publication - Aditi Dey
University College London, Cancer Institute, London, United Kingdom
1 shared publication - Ann Rann Wong
Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by Elsevier in SLAS Discovery
- Vol. 44, 100341
Probing and painting to get the full picture of macrophage polarisation
- 24 September 2026
- Published by Elsevier in SLAS Discovery
- Vol. 44, 100341
Open AccessProbing and painting to get the full picture of macrophage polarisation
- Open Access
- 20 July 2026
- Published by Elsevier in SLAS Discovery
- Vol. 43
From complexity to clarity: Building dashboards for hit selection in high throughput screens
- 20 July 2026
- Published by Elsevier in SLAS Discovery
- Vol. 43
Open AccessFrom complexity to clarity: Building dashboards for hit selection in high throughput screens
- Open Access
- 4 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (21) , 5696-5709
Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts
Cancer-associated fibroblasts (CAFs) arising from bone marrow–derived mesenchymal stromal cells (MSCs) are prominent in B-cell precursor acute lymphoblastic leukemia (B-ALL). We have previously shown that CAF formation is triggered by exposure to reactive oxygen species–inducing chemotherapy and that CAFs support chemoresistance by donating mitochondria to the cancer cells through tunneling nanotubes. In the present study, we show that exposure of MSCs to ALL cell lines, patient-derived xenografts, and primary cells or their conditioned media can also trigger CAF formation. Using bulk RNA sequencing in cell lines, we show that the MSC to CAF transition is accompanied by a robust interferon pathway response, and we have validated this finding in primary cells. Using confocal microscopy and flow cytometry, we identify the uptake of leukemia cell–derived mitochondrial double-stranded RNA (dsRNA) by MSCs as a proximate trigger for the MSC to CAF transition. We demonstrate that inhibiting dsRNA formation in ALL cells by treatment with low-dose ethidium bromide or the mitochondrial transcription inhibitor IMT1, or degrading dsRNA in conditioned media by 100°C exposure eliminates the ability of the ALL conditioned media to stimulate MSC to CAF transition. Our data reveal, to our knowledge, a novel and previously undescribed mechanism by which cancer cells induce a CAF phenotype in stromal cells, showing how B-ALL cells can directly induce the previously described niche-mediated protection within the bone marrow.
- 4 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (21) , 5696-5709
Open AccessMitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts
Cancer-associated fibroblasts (CAFs) arising from bone marrow–derived mesenchymal stromal cells (MSCs) are prominent in B-cell precursor acute lymphoblastic leukemia (B-ALL). We have previously shown that CAF formation is triggered by exposure to reactive oxygen species–inducing chemotherapy and that CAFs support chemoresistance by donating mitochondria to the cancer cells through tunneling nanotubes. In the present study, we show that exposure of MSCs to ALL cell lines, patient-derived xenografts, and primary cells or their conditioned media can also trigger CAF formation. Using bulk RNA sequencing in cell lines, we show that the MSC to CAF transition is accompanied by a robust interferon pathway response, and we have validated this finding in primary cells. Using confocal microscopy and flow cytometry, we identify the uptake of leukemia cell–derived mitochondrial double-stranded RNA (dsRNA) by MSCs as a proximate trigger for the MSC to CAF transition. We demonstrate that inhibiting dsRNA formation in ALL cells by treatment with low-dose ethidium bromide or the mitochondrial transcription inhibitor IMT1, or degrading dsRNA in conditioned media by 100°C exposure eliminates the ability of the ALL conditioned media to stimulate MSC to CAF transition. Our data reveal, to our knowledge, a novel and previously undescribed mechanism by which cancer cells induce a CAF phenotype in stromal cells, showing how B-ALL cells can directly induce the previously described niche-mediated protection within the bone marrow.